Monday, 23 August 2021

Pfizer to buy cancer drug developer Trillium in $3.1b deal

Trillium’s two lead molecules, TTI-622 and TTI-621, block signalling proteins involved in blood cancers, and are both in human trials across several types of disease.

from Sydney Morning Herald - Latest News https://ift.tt/3koKTQ6
via IFTTT

No comments:

Post a Comment